|
Vaccine Detail
Salmonella Typhimurium guaBA/clpP mutant vaccine |
Vaccine Information |
- Vaccine Name: Salmonella Typhimurium guaBA/clpP mutant vaccine
- Target Pathogen: Salmonella spp.
- Target Disease: Salmonellosis
- Product Name: CVD 1921
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- clpP from S. typhimurium str. LT2
gene engineering:
- Type: Gene mutation
- Description: This guaBA/clpP mutant is from Salmonella Typhimurium (Tennant et al., 2011).
- Detailed Gene Information: Click Here.
- guaA from S. typhimurium str. LT2
gene engineering:
- Type: Gene mutation
- Description: This guaBA/clpP mutant is from Salmonella Typhimurium (Tennant et al., 2011).
- Detailed Gene Information: Click Here.
- guaB
gene engineering:
- Type: Gene mutation
- Description: This guaBA/clpP mutant is from Salmonella Typhimurium (Tennant et al., 2011).
- Detailed Gene Information: Click Here.
- Immunization Route: Oral immunization
|
Host Response |
Mouse Response
- Persistence: A guaBA/clpP mutant is attenuated in mice (Tennant et al., 2011).
- Efficacy: A guaBA/clpP mutant induces protection in mice from challenge with wild type Salmonella Typhimurium. The vaccine efficacy is 86% (Tennant et al., 2011).
- Host IgG response
- Description: Immune responses induced included high levels of serum IgG anti-lipopolysaccharide (LPS), with titers increasing progressively during the immunization schedule. Mice immunized with attenuated S. Typhimurium construct CVD 1921 had excellent seroconversion rates after the second immunization and mounted robust antibody responses against both target antigens (LPS and FliC) (Tennant et al., 2011).
- Detailed Gene Information: Click Here.
|
References |
Tennant et al., 2011: Tennant SM, Wang JY, Galen JE, Simon R, Pasetti MF, Gat O, Levine MM. Engineering and pre-clinical evaluation of attenuated non-typhoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infection and immunity. 2011; ; . [PubMed: 21807911].
|
|